STF 083010

Key Product Details

Product Description

STF 083010 is a inhibitor of IRE1α endonuclease activity; blocks endogenous XBP1 mRNA splicing. Displays cytostatic and cytotoxic effects in CD138⁺ multiple myeloma (MM) cells in vitro; inhibits bortezomib-induced XBP1 activity in myeloma xenografts in vivo. Does not alter IRE1α kinase activity.

Product Specifications for STF 083010

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for STF 083010

The following data is based on the product molecular weight 317.38.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	3.15 mL	15.75 mL	31.51 mL
5 mM	0.63 mL	3.15 mL	6.30 mL
10 mM	0.32 mL	1.58 mL	3.15 mL
50 mM	0.06 mL	0.32 mL	0.63 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 15 publications citing the usage of this product.

• Kraskiewicz and FitzGerald InterfERing with endoplasmic reticulum stress. Trends Pharmacol.Sci. 2012 PMID: 22112465
• Papandreou Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood. 2011 PMID: 21081713

Product Documents for STF 083010